Specops Medical Supply, LLC

Specops Medical Supply, LLC, a Service-Disabled Veteran-Owned Small Business headquartered in McKinney, Texas, manufactures and supplies neuromuscular stimulation devices, prosthetics, orthotic equipment, and related medical rehabilitation technologies to the Department of Veterans Affairs as a prime contractor operating predominantly under full-and-open competition on the VA's Medical Equipment and Supplies GSA Schedule (FSS-65-II-A).

Specops competes across 857 federal awards spanning delivery orders and purchase orders, with 100% of recorded activity as prime work. The company holds dual SBA certifications as both a Veteran-Owned Small Business and Service-Disabled Veteran-Owned Small Business through October 25, 2027. Core capability encompasses L300 GO Systems and Bioness functional electrical stimulation devices (neuromuscular stimulation for rehabilitation), prosthetic limbs and components, vein visualization systems (vein finders and vein viewers), bone and muscle stimulators, custom mobility devices, and surgical implants. Representative delivery orders include a $42.7 million Functional Electrical Stimulator System for VISN 22 in May 2025, a $56.2 thousand express reporting order on medical orders placed through September 2025, and $34.5 million in L300 GO Systems delivered to VISN 17 in June 2025.

Customer concentration is heavily skewed to the VA. The top five customer VISNs by award count account for 48% of awards: VISN 8 leads with 141 awards ($2.9 million combined potential value), followed by VISN 17 (79 awards, $3.1 million), VISN 6 (77 awards, $2 million), VISN 7 (62 awards, $1.5 million), and VISN 10 (49 awards, $863 thousand). By potential value, however, VISN 12 dominates with 32 awards carrying $160 million in combined potential value—a single outlier reflecting Specops' seat on a large multi-year supply agreement. VA Headquarters accounts for 8 awards worth $9.1 million. This divergence signals that while Specops executes numerous small-dollar delivery orders across multiple regional networks, a substantial portion of its pipeline value concentrates in a handful of master vehicles and regional agreements, particularly with VISN 12.

Specops holds a Federal Supply Schedule contract awarded June 1, 2026, with a $157.2 million ceiling through May 31, 2031, under FSS-65-II-A (Medical Equipment and Supplies). The Medical Equipment and Supplies vehicle anchors the portfolio with 428 task orders valued at $7 million. Two additional indefinite delivery contracts—36C25719D0060 and 36C10G22D0005—carry 20 combined task orders worth roughly $894 thousand. Set-aside posture varies by award: the company competes predominantly under full-and-open competition but has received SDVOSB Sole Source and Total Small Business set-aside awards, including eye clinic chairs ($16.8 thousand, SDVOSB set-aside, January 2026) and an integrated therapy system ($13.8 thousand, Total Small Business, June 2025). This mixed approach reflects Specops' ability to leverage veteran-owned status opportunistically while maintaining broader competitive reach.

Activity trajectory shows growth from 2022 through 2024—69 to 134 to 155 awards year over year—followed by a contraction to 139 awards in 2025 and only 6 awards recorded through June 2026 (reflecting the recency of the source snapshot). Eleven awards with completion dates inside the next twenty-four months carry $671 thousand in combined potential value, presenting moderate recompete exposure. The vast majority of Specops' federal work derives from the VA's distributed VISN ordering system; the company has no recorded subcontract or sub-award activity, operates as 100% prime, and shows no teaming relationships or parent prime dependencies. NAICS concentration is surgical appliance and supplies manufacturing (585 awards), surgical and medical instrument manufacturing (123 awards), and electromedical apparatus manufacturing (93 awards), with corresponding PSC concentration in medical and surgical instruments and equipment (782 awards).